KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance

KORU Medical Systems, Inc.

2024-Q3 EPS reported -$0.10 revenue$24,807,864

Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
Core revenue $7.6M (+11% YoY); novel therapies $0.6M (+276% YoY).
Net loss $1.6M ($0.03 diluted EPS); adjusted EBITDA loss $0.4M.
Raises FY 2024 revenue guidance to $32.75-33.25M (15-17% growth) from $32.0-32.5M.
Raises FY 2024 gross margin guidance to 62-63%; year-end cash guidance >$8.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.